Global Diabetes Care Drugs & Devices Market - 2025-2033

The global diabetes care drugs & devices market reached US$ 119.86 billion in 2024 and is expected to reach US$ 244.46 billion by 2033, growing at a CAGR of 8.3% during the forecast period 2025-2033.

Diabetes care drugs & devices refer to the pharmaceutical treatments and medical devices designed to help manage, monitor and control diabetes, a chronic metabolic disorder characterized by high blood glucose levels. These drugs and devices play a crucial role in preventing diabetes-related complications such as cardiovascular diseases, neuropathy, nephropathy and retinopathy.

Diabetes care drugs are medications that help regulate blood sugar levels by enhancing insulin production, improving insulin sensitivity, or reducing glucose absorption. These drugs are categorized into various classes based on their mechanism of action. Diabetes care devices are medical tools and equipment that assist in monitoring, administering treatments, and managing diabetes effectively. These devices improve accuracy, convenience, and patient compliance in diabetes management.

The diabetes care drugs and devices market is experiencing significant growth, driven by the increasing prevalence of diabetes worldwide and advancements in diabetes care drugs and devices. Innovations in continuous glucose monitoring systems, insulin pumps, and smart insulin pens have enhanced diabetes management, leading to increased adoption of these devices. Integrating digital health solutions, such as mobile applications and wearable technology, has further propelled market growth.

For instance, in September 2024, Senseonics Holdings, Inc. and Ascensia Diabetes Care received the U.S. Food and Drug Administration (FDA) clearance for the next-generation Eversense 365 CGM system for people with Type 1 and Type 2 diabetes aged 18 years and older. Eversense 365 is the world’s first One-year CGM system, representing a significant breakthrough in diabetes technology and management.

Market Dynamics: Drivers & Restraints

Rising prevalence of diabetes

The rising prevalence of diabetes is significantly driving the growth of the diabetes care drugs and devices market and is expected to continue driving the market over the forecast period. The global prevalence of diabetes is rising sharply due to lifestyle changes, aging populations, and rising obesity rates. This surge in cases creates a higher demand for diabetes drugs and care devices.

For instance, according to the International Diabetes Federation, in 2021, 536.6 million adults (20-79 years) are living with diabetes i.e., 1 in 10 people. This number is predicted to rise to 642.8 million by 2030 and 783.7 million by 2045. Over 3 in 4 adults with diabetes live in low- and middle-income countries. This escalating prevalence highlights the urgent need for diabetes care drugs and devices.

As diabetes progresses, patients require regular monitoring and consistent medication to manage their blood glucose levels. This increases demand for blood glucose monitoring devices such as SMBG systems, continuous glucose monitors, insulin delivery devices such as insulin pumps, pens and diabetes drugs insulin, oral hypoglycemics for better diabetes management. In addition to the rising demand, market players are constantly focused on innovations and launching products that meet the demand.

For instance, in August 2024, Insulet Corporation cleared that its groundbreaking Omnipod 5 Automated Insulin Delivery System (Omnipod 5) is now indicated for use by people with type 2 diabetes (ages 18 years and older) in the U.S., making it the first and only AID system FDA-cleared for both type 1 and type 2 diabetes management.

Additionally, in June 2024, AstraZeneca cleared the US Food and Drug Administration (FDA) approval for Farxiga (dapagliflozin) to improve glycaemic control in pediatric patients with type-2 diabetes (T2D) aged 10 years and older. The FDA approval was based on positive results from the pediatric T2NOW Phase III trial. Farxiga was previously approved in the US in adults with T2D as an adjunct to diet and exercise to improve glycaemic control.

High cost of diabetes care devices

Advanced diabetes care devices such as continuous glucose monitors (CGMs) and insulin pumps can cost anywhere high for sensors and maintenance, not including the upfront costs of the devices themselves. Such high costs limit their adoption, especially in developing regions where these advanced technologies are considered unaffordable.

For instance, according to the National Institute of Health, the costs of CGM are substantially offset if device costs are added, with an average of $4,431 during the 12-month follow-up versus $319 for blood glucose monitor. Additionally, a Dexcom G6 transmitter costs $366 without insurance for one device that lasts 90 days. The Dexcom G6 CGM system can cost around $8,000 annually out-of-pocket, excluding a receiver for non-smartphone users ($540) and a compatible phone.

Segment Analysis

The global diabetes care drugs & devices market is segmented based on product type, application, end-user and region.

The diabetes devices in the product type segment are expected to be the fastest growing segment of diabetes care drugs & devices market

The demand for blood glucose monitoring devices including both self-monitoring blood glucose (SMBG) systems and continuous glucose monitoring (CGM) systems has significantly increased as patients and healthcare providers seek better, more accurate ways to manage diabetes. Thus, rising demand drives the market players to launch advanced devices. For instance, in August 2024, Medtronic plc cleared the U.S. Food and Drug Administration (FDA) approval for its Simplera continuous glucose monitor (CGM). The discreet design simplifies the insertion and wear experience, eliminating the need for overtape.

Insulin pumps and insulin pens are widely used to manage insulin-dependent diabetes, particularly for Type 1 diabetes patients. Insulin pens, more affordable and portable than pumps, have become essential for diabetes management, leading to steady growth in their adoption. Thus, major and emerging players are focussing on the development of advanced insulin pumps. For instance, in September 2024, Modular Medical, Inc. received U. S. Food and Drug Administration clearance to market and sell its MODD1 pump in the United States.

The integration of technology into diabetes care devices has made the market players develop more user-friendly and efficient devices, increasing their market dominance. For instance, in October 2024, Ascensia Diabetes Care launched the Eversense 365 continuous glucose monitoring (CGM) system, the world’s only One Year CGM, for people with diabetes in the U.S. Developed by Senseonics Holdings, Inc., Eversense 365 is the only CGM that provides one year of accurate monitoring with minimal disruptions, enabling confident decisions, long-term peace of mind, and enhanced quality of life with just one CGM.

Geographical Analysis

North America is expected to hold a significant position in the diabetes care drugs & devices market with highest market share

North America, especially the United States, has one of the highest diabetes rates globally, significantly driving the demand for diabetes care products. For instance, according to the Centers for Disease Control and Prevention (CDC), in the U.S., approximately 38.4 million people of all ages (about 11.6% of the population) have diabetes. This high prevalence fuels both the demand for diabetes drugs such as insulin and oral medications and advanced monitoring and delivery devices such as CGMs and insulin pumps.

North America particularly the United States and Canada is home to some of the major leading companies in the diabetes care market, including Medtronic, Abbott Laboratories, Dexcom, Roche, Merck & Co., Inc. and Novo Nordisk. These companies significantly influence market trends by innovative product launches, drive innovations and contribute to the availability and distribution of cutting-edge diabetes care drugs and devices.

For instance, in June 2024, Abbott’s world-leading FreeStyle Libre portfolio of continuous glucose monitors has revolutionized the way roughly 6 million people worldwide manage their diabetes. The FDA also cleared Libre Rio, Abbott’s first over-the-counter CGM system for people with diabetes in the United States. Libre Rio is designed for people ages 18 years and older with Type 2 diabetes who do not use insulin and typically manage their diabetes through lifestyle modifications.

Asia-Pacific is growing at the fastest pace in the diabetes care drugs & devices market

The Asia-Pacific region is witnessing a significant rise in diabetes cases due to changing lifestyles, urbanization and an aging population. For instance, the International Diabetes Federation (IDF) reports that by 2045, over 200 million people in the APAC region are projected to have diabetes, making it the region with the highest number of diabetes cases globally. Countries like China, India, Japan and Indonesia are experiencing rapid increases in diabetes prevalence due to urbanization and growing health risk factors like obesity and sedentary lifestyles.

As the number of diabetic patients rises, the demand for both diabetes care drugs and diabetes devices is expanding along with advancements in diabetes care devices and drugs, which helps market players to develop advanced drugs and devices. For instance, in April 2024, Sanofi India Limited launched a new diabetes drug Soliqua after receiving marketing authorization from the Central Drugs Standard Control Organisation (CDSCO), indicated as a treatment in adults with obesity and type 2 diabetes mellitus, to improve glycemic control as an adjunct to diet and exercise.

Additionally, in November 2024, Beurer India Pvt. Ltd. officially launched the GL 22 Blood Glucose Monitor. The GL 22 Blood Glucose Monitor combines German precision with advanced technology designed to meet local needs. The device features comprehensive monitoring capabilities, including average readings for 7, 14, 30 and 90 days, offering crucial insights into blood glucose trends. These features closely align with HbA1c levels, a critical marker for long-term blood sugar control, ensuring users and healthcare providers can manage diabetes more effectively.

Competitive Landscape

The major global players in the diabetes care drugs & devices market include F. Hoffmann-La Roche Ltd, Abbott Laboratories, Medtronic plc, Terumo Corporation, B. Braun SE, Merck & Co., Inc., Novo Nordisk A/S., Eli Lilly and Company, Boehringer Ingelheim Pharmaceuticals, Inc., Insulet Corporation and among others.

Why Purchase the Report?
• Pipeline & Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
• Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
• Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
• Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
• Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
• Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
• Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
• Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
• Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
• Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
• Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
• Post-market Surveillance: Uses post-market data to enhance product safety and access.
• Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global diabetes care drugs & devices market report delivers a detailed analysis with 62 key tables, more than 54 visually impactful figures, and 179 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2024
• Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
• Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
• Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
• Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
• Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
• Supply Chain: Distribution and Supply Chain Managers.
• Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
• Academic & Research: Academic Institutions.